Synthetic Biologics (SYN) Reports In-Line Q2 EPS

Synthetic Biologics (NYSE: SYN) reported Q2 EPS of ($0.02), in-line with the analyst estimate of ($0.02).

Cash and cash equivalents as of June 30, 2021 totaled $74.3 million, an increase of $68.1 million from December 31, 2020.

For earnings history and earnings-related data on Synthetic Biologics (SYN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Independent Bank receives regulatory approval for HCB Financial acquisition
• Sharon AI surges premarket; New Oriental gains, Medline slips